Novavax COVID-19 vaccine ‘Covavax’ expected to launch in India by September
First Published: 17th June, 2021 22:26 IST
The Serum Institute of India (SII) hopes to introduce US firm Novavax’s Indian version of the COVID-19 vaccine – ‘Covavax’ by September this year and start trials on children from
The Serum Institute of India (SII) hopes to introduce US firm Novavax’s Indian version of the COVID-19 vaccine – ‘Covavax’ by September this year and start trials on children from July, sources said on Thursday.
The SII is hoping to introduce Covavax in the country by September which is a version of US firm Novavax’s Covid-19 vaccine, sources added.
Earlier this week, Novavax’s vaccine exhibited a 90.4 per cent overall efficacy in Phase-3 clinical trials. That puts it in the same bracket as two of the frontline vaccines being used in the US and European countries, the ones produced by Pfizer-BioNTech and Moderna, which had efficacy rates of 91.3 per cent and 90 per cent in Phase 3 trials, respectively.
“Serum Institute plans to start clinical trials of the Novavax shot for Children in July,” sources confirmed to ANI.
Earlier on Tuesday, the Centre said that recently declared Novavax Covid vaccine efficacy data in a large trial are promising and that clinical trials are being conducted and are in an advanced stage of completion in India.
“What we’re learning from data available in the public domain that this vaccine is very safe and highly effective. It’ll be produced in India,” said Dr VK Paul, Member-Health, Niti Aayog said in a routine briefing by the Union Health Ministry on the COVID-19 situation in India.
He also added that gap in the production of Novavax’s vaccine was likely for a while.
“I am also hoping they (US company Novavax) would also start trials on children too,” Paul had said.
Novavax’s vaccine candidate has partnered with Pune-based vaccine manufacturer Serum Institute of India to produce doses in India.
Meanwhile, the All India Institute of Medical Sciences (AIIMS) in Delhi from Tuesday began the screening of children in the age group of 6 to 12 years for the clinical trials of Covaxin, the indigenously developed Covid-19 vaccine.
AIIMS Delhi has already completed the clinical trial for a single dose of Covaxin for children aged 12-18 age group.
The United States of America had in May approved Pfizer’s COVID-19 vaccine for use in children as young as 12. Pfizer’s shot is the first to be cleared in the United States for children 12 to 15. (ANI)
COMMENTS
TOPMOST STORY NOW
Live Hyderabad police summon Allu Arjun in connection with Sandhya theatre incident
24th December 2024Live M’laya Minister Paul Lyngdoh Wishes Everyone A Very Happy Merry Christman And A Happy New Year
24th December 2024Live Grand Finale of Miss Trans NE 2024 Held in Guwahati
24th December 2024Live Naga Civil Society Organisation In Manipur Condemns Brutal Attack on Senapati District Students Association Executives
23rd December 2024WE RECOMMEND
Epigamia Co-Founder Rohan Mirchandani Passes Away at 41 Due to Heart Attack
The company’s leadership decided to continue to manage the business.
23rd December 20247 Indian nationals injured in Magdeburg Christmas market attack
Of these,three have been discharged from the hospital, while the Indian Mission is closely monitoring the condition of the remaining victims.
22nd December 2024Nagaland MP Accuses Rahul Gandhi of Standing Too Close to Her, Making Her Feel Uncomfortable
MP Phangnon Konyak has filed a complaint with Rajya Sabha Chairman against Congress leader Rahul Gandhi
19th December 2024GRAP Stage IV reintroduced in NCR as AQI breaches 400 mark
This comes after the Air Quality Index in Delhi breached the 400 mark. AQI was recorded as 399 at 9 pm and 401 at 10 pm.
17th December 2024India, Bangladesh to commemorate 1971 war ‘Vijay Diwas’ with annual exchange of veterans today
The event also gave an opportunity to the tribal community to showcase their talent.
16th December 2024